0
Vaccimed, the biotechnology Chilean company developed an innovative vaccine for the immunocastration of pigs, which uses the mammalian immune system to develop safely and efficiently the procedure without surgery. Due to its multiple benefits, the VencoFarma Brazilian company of veterinary products, acquired the commercialization and production rights of the vaccine for pigs for a total of US$10 million.
This scientific innovation, unique in the world, allows controlling the fertility, aggressiveness, and the production of sex hormones in animals as well as the surgical castration.
Because of this new technology, that seeks harmony with the animal welfare, the traditional castration is not necessary. Important scientific, social, and commercial projections for pig producers is reflected, by eliminating the associated complications such as stress, mortality, and infections and responding to the new requirements related to the animal welfare.
The immunocastration is an immunological alternative focused on the management of the reproductive activity in animals, in a safe and effective way. This vaccine is produced from a recombinant molecule. It acts by blocking the production of sex steroids and the reproductive activity through the immunoneutralization of the GnRH-I hormone in mammals.
The results are eloquent: the conversion rate has improved because of the immunocastration of pigs, the producers will be prepared to the compliance of future regulations, they will obtain leaner meats and they will save up to US$5 per pig a month.
December 20, 2013 - Vaccimed
